U.S. Vaccine Panel Opts Not to Vote on J&J Covid-19 Vaccine Clot Risk
By Betsy McKay and Peter Loftus By
A federal advisory panel Wednesday declined to vote on how
Johnson & Johnson's Covid-19 vaccine should be used, saying it
needs more time to gather information on the risk of the vaccine
following reports of cases of rare but severe blood clots that
developed in a few recipients.
The Advisory Committee on Immunization Practices, or ACIP, said
Wednesday it doesn't have enough information yet about the risk of
these unusual side effects to determine whether the vaccine should
be continued, discontinued or recommended only for certain groups
of the population.
The ACIP expects to meet again in another week or two to revisit
the issue. U.S. health officials on Tuesday recommended that use of
the J&J vaccine be paused while they investigate.
The ACIP, which advises the Centers for Disease Control and
Prevention on vaccination policy, met to review clinical data
gathered to date on six women between the ages of 18 and 48 years
old who developed clots in vessels draining blood from their brains
and in some cases other parts of the body after receiving J&J's
vaccine. More than 7.2 million doses of the J&J vaccine have
been administered in the U.S.; about 1.5 million of those doses
went to women between ages 18 and 50 years.
While Wednesday's discussion was limited to six cases, CDC
officials said they expect more will come to light, either cases
that have gone unrecognized or that may yet occur. About 52% of the
J&J doses to date were administered within the past two
(More to come)
Write to Betsy McKay at firstname.lastname@example.org
(END) Dow Jones Newswires
April 14, 2021 17:58 ET (21:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.